Neurocrine Biosciences has initiated a Phase 1 clinical trial to test the safety and tolerability of NBIP-'1968, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors for obesity treatment. This investigational drug aims to address obesity by engaging three metabolic mechanisms to regulate appetite, energy balance, and glycemic control. The study will involve single ascending doses in adults with varying body mass indexes. NBIP-'1968 is part of Neurocrine's broader obesity portfolio, which includes other investigational drugs, reflecting the company's commitment to developing new therapies for this complex chronic disease with significant health impacts worldwide.
Neurocrine Biosciences published expert perspectives emphasizing hyperphagia in Prader-Willi syndrome (PWS) as a complex condition requiring integrated care. The experts highlight the multidimensional nature of hyperphagia, involving biological, beha...
Neurocrine Biosciences has launched a Phase 2 clinical trial for NBI-1117567 (NBI-'567), an oral drug targeting muscarinic receptors to improve cognition in adults with mild to moderate Alzheimer's disease. The study will test the drug's efficacy and...
